SCHEMBL5323549

SCHEMBL5323549

CN(Cc1ccccc1)C(CCCO)c1cccc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
TMEM97 Q5BJF2 2/20 0.43
SIGMAR1 Q99720 2/20 0.43
LMNA P02545 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SLC6A2 P23975 3/20 0.40
SLC6A4 P31645 3/20 0.40
TSHR P16473 1/20 0.39
RECQL P46063 1/20 0.39
OPRM1 P35372 2/20 0.39
OPRD1 P41143 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
ADRA2B P18089 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5325814 0.86 TMEM97 (0.42) TMEM97SIGMAR1SLC6A2SLC6A4ADRA2B
SCHEMBL5321066 0.85 NPSR1 (0.39) GAATMEM97SIGMAR1LMNACYP1A2
SCHEMBL5322144 0.81 LMNA (0.47) GAATMEM97SIGMAR1LMNACYP1A2
SCHEMBL5164752 0.78 HTR2A (0.47) SLC6A2SLC6A4TSHRADRA2BADRA2C
SCHEMBL4739767 0.78 UTS2R (0.42) TMEM97SIGMAR1LMNACYP1A2CYP3A4
SCHEMBL5397721 0.76 SLC6A2 (0.40) SLC6A2SLC6A4OPRM1OPRD1OPRK1
SCHEMBL11298724 0.72 OPRM1 (0.46) SLC6A2SLC6A4OPRM1OPRD1OPRL1
SCHEMBL14017766 0.72 ADRA2B (0.50) GAANPSR1SLC6A2SLC6A4TSHR
SCHEMBL13452589 0.72 ADRA2B (0.50) GAANPSR1SLC6A2SLC6A4TSHR
SCHEMBL31419982 0.71 MEN1 (0.58) GAATMEM97SIGMAR1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007095756-A1 NOVEL CENTRAL-NERVOUS SYSTEM ACTING COMPOUNDS AND METHODS FOR THE TREATMENT OF CNS DISORDERS CLERA INC. (CA) 2007-08-30 WO disclosed